bioAffinity Technologies, Inc. (BIAF) Operating Margin
- Operating margin · 12 months: Value -209.82%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -209.82% | Operating income / revenue. Period ending 2026-06-30. $-12.38M ÷ $5.90M × 100 ≈ -209.82% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -12.38M USD | Operating Income (Loss) |
| Revenue | 5.90M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 1.42M USD | Research and Development Expense |
| Selling, general and administration | 11.35M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-12.38M | $5.90M | (m) | $1.42M | $11.35M | -209.82% |
| 2026-03-31 | $-11.56M | $5.66M | (m) | $1.37M | $10.70M | -204.29% |
| 2025-12-31 | $-10.57M | $6.16M | (m) | $1.38M | $9.91M | -171.58% |
| 2025-09-30 | $-10.38M | $6.78M | (m) | $1.40M | $9.80M | -153.20% |
| 2025-06-30 | $-10.06M | $7.68M | (m) | $1.34M | $9.95M | -131.01% |
| 2025-03-31 | $-9.64M | $8.81M | (m) | $1.43M | $10.21M | -109.38% |
| 2024-12-31 | $-8.95M | $9.36M | (m) | $1.46M | $9.94M | -95.64% |
| 2024-09-30 | $-8.35M | $9.37M | (m) | $1.50M | $9.24M | -89.13% |
| 2024-06-30 | $-8.67M | $7.32M | (m) | $1.56M | $8.90M | -118.51% |
| 2024-03-31 | $-8.36M | $4.94M | (m) | $1.49M | $7.83M | -169.31% |
| 2023-12-31 | $-7.97M | $2.53M | (m) | $1.47M | $6.79M | -314.84% |
| 2023-09-30 | $-7.25M | $321.49K | (m) | $1.23M | $6.01M | -2256.55% |
| 2023-06-30 | $-5.94M | $24.16K | (m) | $1.32M | $4.52M | -24574.50% |
| 2023-03-31 | $-4.84M | (m) | (m) | $1.23M | $3.50M | (m) |
| 2022-12-31 | $-4.01M | $4.80K | (m) | $1.14M | $2.73M | -83511.51% |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-2.21M | (m) | (m) | $1.01M | $1.07M | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |